Ligand to Participate in June Investor Conferences
Rhea-AI Summary
Ligand (Nasdaq: LGND) announced participation in two June 2026 investor conferences. At the Stifel 2026 Boston Cross Sector 1x1 Conference, management will hold one-on-one investor meetings on June 3, 2026 in Boston.
At the Goldman Sachs 47th Annual Global Healthcare Conference, management will host a fireside chat on June 10, 2026 at 10:00 a.m. ET in Miami, followed by one-on-one meetings.
Positive
- None.
Negative
- None.
News Market Reaction – LGND
In the May 28 session, LGND declined 0.52%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2026-05-07 | Q1 2026 earnings | Positive | -9.6% | Strong Q1 revenue, royalty growth and reaffirmed 2026 guidance. |
| 2026-05-05 | Investor conferences | Neutral | +0.1% | Announcement of management participation in multiple May investor conferences. |
| 2026-04-27 | XOMA acquisition | Positive | +4.5% | Agreement to acquire XOMA Royalty, expanding royalty assets and raising guidance. |
| 2026-04-22 | Earnings date set | Neutral | -0.1% | Scheduling of Q1 2026 earnings call and webcast details. |
| 2026-04-14 | Partner FDA approval | Positive | +8.8% | Partner Travere gained full FDA approval for FILSPARI with 9% royalty to Ligand. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
LGND has reacted positively to strategic and partner milestones but showed a notable selloff after a fundamentally strong earnings report, indicating occasional divergence between fundamentals and near-term price moves.
Over recent months, Ligand reported Q1 2026 results with $51.7M total revenue and strong royalty growth, yet shares fell 9.55% the next day. The stock reacted well to the announced acquisition of XOMA Royalty and raised 2026 guidance, gaining 4.55%. A partner’s full FDA approval for FILSPARI in FSGS drove an 8.85% gain, highlighting the value of the royalty portfolio. Prior news on earnings timing and investor conferences had negligible price impact, similar in nature to today’s conference-participation announcement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
JUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences:
- Stifel 2026 Boston Cross Sector 1x1 Conference. Management will participate in one-on-one meetings with investors on June 3, 2026 in Boston.
- Goldman Sachs 47th Annual Global Healthcare Conference. Management will participate in a fireside chat on June 10, 2026 at 10:00 a.m. ET in Miami followed by one-on-one meetings with investors.
Investors interested in arranging one-on-one meetings should contact their Stifel or Goldman Sachs representative.
About Ligand Pharmaceuticals
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 100 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn.
Contacts
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
